bioAffinity Technologies Inc. (BIAF) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BIAF currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.15) and Max Pain ($3.18) forces dealer call-delta covering toward $84.74.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
bioAffinity Technologies Inc. (BIAF) dropped -3.50% to $3.03, trading at 2% of its 52-week range ($2.66 – $80.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SAN ANTONIO, October 29, 2026--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event.
bioAffinity Technologies CEO Maria Zennes joined Steve Darling from Proactive to discuss the company's noninvasive lung cancer detection technology, reported 200% year-over-year growth in the second quarter, insurance re
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -34.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIAF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIAF. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, bioAffinity Technologies Inc. (BIAF) ranks #905 by composite RQD confidence (32/100, grade E) and #964 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with BIAF at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BIAF
ACTIVE
bioAffinity Technologies Inc. | E | 32/100 | — | — | -35.0% | -3.50% | $3.9M | Benchmark Subject |
| ISPC iSpecimen Inc. | D- | 39/100 | — | 11.2% | -35.0% | -9.35% | $2.0M | /ispc-vs-biaf → |
| ONMD OneMedNet Corp (Class A) | E | 29/100 | — | -30.0% | -35.0% | -2.02% | $26.3M | /onmd-vs-biaf → |
| MXCT MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | /mxct-vs-biaf → |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-biaf → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), bioAffinity Technologies Inc. (BIAF) reported GAAP revenue of $6.2M (-34.2% vs. FY2024 revenue of $9.4M , and +143.3% cumulative change since FY2023) , GAAP net income of -$14.9M, operating cash flow of -$9.3M, and free cash flow of -$9.4M (-27.9% YoY). On the balance sheet, BIAF closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.2M | -$14.9M | -$9.3M | -$9.4M | $11.0M | — |
| FY2024 (FY) | 2024-12-31 | $9.4M | -$9.0M | -$7.3M | -$7.3M | $6.5M | — |
| FY2023 (FY) | 2023-12-31 | $2.5M | -$7.9M | -$6.0M | -$6.0M | — | — |
As of 2026-11-01, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.03 (-3.50% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BIAF ranks #905 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.0M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $26.3M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BIAF last traded at $3.03 (-3.50% on volume of 326,533 shares), positioning the stock -50.73% below its 50-day simple moving average ($6.15) and -84.26% below its 200-day simple moving average ($19.25). Across its 52-week range of $2.66 to $80.70, BIAF sits at the 0.5% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.65 to $3.41).
Why BIAF Stock dropped -3.50% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.